Clinical trial
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed…
NCT00471497 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00471497 |
|---|---|
| Title | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) |
| Official title | A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) |
| Acronym | ENESTnd |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelogenous Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | nilotinib, imatinib |
| Enrollment | 846 |
| Start date | Jul 31, 2007 |
| Primary completion | Sep 2, 2009 |
| Completion | Aug 21, 2019 |
| First posted | May 10, 2007 |
| Last update posted | Nov 18, 2020 |
| Countries | Argentina, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Egypt, Finland, France, Germany and 23 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: